Bela F. Asztalos, Ph.D.

Selected HNRCA Research Publications
	Scientist I Lipid Metabolism Laboratory Jean Mayer USDA HNRCA at Tufts University 711 Washington Street Boston, MA 02111-1524 Phone: (617) 556-3112 Fax: (617) 556-3103 E-Mail: bela.asztalos@tufts.edu
Education	Ph.D., Biochemistry Attila Jozsef University, Szeged, Hungary
Research Focus	HDL metabolism, structure and function; cardiovascular disease risk reduction; relationship between nutrition, aging, lipoproteins and cardiovascular disease risk.
Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. Journal of Lipid Research. 2007;48(3):592-599. Yancey, P.G., Asztalos, B.F., Stettler, N., Piccoli, D., Williams, D.L., Connelly, M.A., Asztalos, B., De La Llera-Moya, M., Dallal, G., Hovath, K.V., Schaefer, E., Rothblat, G.H. Differential effects of HDL subpopulations on cellular abca1- and sr-bi-mediated cholesterol efflux. Journal of Lipid Research. 2005;46(10):2246-53. Asztalos, B.F., Horvath, K.V., Kajinami, K., Nartsupha, C., Cox, C.E., Batista, M., Asztalos, B.F., Collins, D., Cupples, L., Demissie, S., Horvath, K.V., Bloomfield, H.E., Robins, S.J., Schaefer, E.J. Value of high-density lipoprotein (hdl) subpopulations in predicting recurrent cardiovascular events in the veterans affairs hdl intervention trial. Arteriosclerosis Thrombosis and Vascular Biology. 2005;25(10):2185-91. Asztalos, B.F., Cupples, A.L., Demissie, S., Horvath, K.V., Cox, C.E., Batista, M.C., Schaefer, E.J. High-density lipoprotein subpopulation profile and coronary artery disease prevalence in male participants of the Framingham Offspring Study. Arteriosclerosis Thrombosis and Vascular Biology. 2004;24:2181-2187. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arteriosclerosis Thrombosis and Vascular Biology. 2003;23(5):847-852.
Other Recent Publications Schaefer EJ, Asztalos BF. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Current Opinions in Cardiology. 2007;22(4):373-8. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, Dolnikowski GG, Horvath K, Asztalos BF, Zago V, Schaefer EJ. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. Journal of Lipid Research. 2007;48(8):1746-53. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. American Journal of Cardiology. 2007;99(5):681-5. Schaefer EJ, Asztalos BF. Should we target HDL-cholesterol to reduce coronary heart disease risk? Nature clinical practice:: Endocrinology & metabolism. 2006;2(7):358-9. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Current Opinion in Lipidology. 2006;17(4):394-8. Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Current Atherosclerosis Reports. 2006;8(1):41-9. Asztalos BF, Demissie S, Cupples LA, Collins D, Cox CE, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis. 2006;188(1):59-67. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arteriosclerosis Thrombosis and Vascular Biology. 2005;25(10):2185-91. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res. 2005;46(10):2246-53. Asztalos BF, Schaefer EJ, Horvath KV, Cox CE, Skinner S, Gerrior J, Gorbach SL, Wanke C. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006;184(1):72-7. To see more of Dr. Bela Asztalos's publications, please visit PubMed and search for "Asztalos B."